Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 168.29% from the stock’s current price.
CLDX has been the topic of a number of other reports. Citigroup started coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.
Read Our Latest Research Report on CLDX
Celldex Therapeutics Price Performance
Insider Activity at Celldex Therapeutics
In other news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The stock was bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.80% of the stock is owned by company insiders.
Institutional Investors Weigh In On Celldex Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Novo Holdings A S boosted its position in Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after buying an additional 113,663 shares in the last quarter. Jennison Associates LLC grew its position in Celldex Therapeutics by 32.0% during the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Celldex Therapeutics by 293.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock worth $958,000 after purchasing an additional 21,013 shares in the last quarter. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Celldex Therapeutics during the third quarter worth about $871,000.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
- Five stocks we like better than Celldex Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- 3 Steel Stocks Soaring After Tariff Announcements
- Quiet Period Expirations Explained
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- How to Invest in the FAANG Stocks
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.